KR20230089824A - Composition for anti-obesity - Google Patents

Abstract

The present invention relates to a composition for anti-obesity, and more particularly, to provide a health food composition and pharmaceutical composition for anti-obesity containing caftaric acid or a pharmaceutically or food-acceptable salt thereof as an active ingredient. do.
The composition exhibits excellent anti-obesity activity by suppressing the differentiation of preadipocytes into adipocytes, thereby suppressing the production of lipid droplets or promoting their decomposition, and by using this composition, obesity or obesity-related diseases are more safely and effectively treated. It can be prevented, ameliorated or cured.

Description

Composition for anti-obesity {COMPOSITION FOR ANTI-OBESITY}

The present invention relates to a composition for anti-obesity, and more particularly, to a health food composition and pharmaceutical composition for anti-obesity containing caftaric acid or a pharmaceutically or food-acceptable salt thereof as an active ingredient. will be.

Recently, the pharmaceutical industry is actively working on the development of obesity treatment drugs. As the number of obese people continues to increase both domestically and globally, and as the number of patients who recognize obesity as a disease and take medicines is increasing, expectations for the related market are rising. The World Health Organization predicts that the global obesity treatment market will expand from 1.1 billion dollars (1.26 trillion won) in 2016 to 24.1 billion dollars (27 trillion won) in 2027, growing at an average annual rate of 32.8%.

Obesity is a state in which adipose tissue is excessive in the body, and obesity is induced by energy imbalance when nutrients are excessively consumed compared to energy consumption. In some cases, it may be caused by a genetic mutation in a specific gene, a problem with the appetite control center function, an endocrine disease such as Cushing's syndrome, or various drugs that increase appetite, but in general, energy intake is greater than energy consumption. . General obesity is caused by a combination of genetic and environmental influences. In particular, the modern living environment in which high-calorie foods are abundant and there is no inconvenience in living even with less physical activity is causing an explosive increase in obesity.

In addition, obesity is a risk factor that increases the possibility of various diseases such as diabetes, circulatory system disease, and cancer. It is recognized as a serious problem that not only threatens public health, but also causes enormous social costs and damages national competitiveness.

Appetite suppressants, thermogenics, diuretics and the like are currently being used as such anti-obesity drugs. Among them, the most commonly used appetite suppressants act on the hypothalamus of the brain to have a mechanism of action that exhibits a weight loss effect due to appetite suppression, and most of them are known to induce central nervous stimulation to induce their action. However, in the case of most of these appetite suppressants, the ability to suppress appetite is not sustained and there is a problem of causing side effects such as headache, insomnia, blood pressure increase, nervousness, nervousness, hallucination symptoms, dizziness, and blurred vision due to temporary action. It is also known that some appetite suppressants have psychological and physical dependence. Therefore, it is necessary to develop a technology that can more safely achieve the anti-obesity effect.

Republic of Korea Patent Publication No. 10-2007-0022539 (published on February 27, 2007)

An object of the present invention is to provide a composition that is safe and has excellent anti-obesity effects.

In order to achieve the above object, the present invention provides a health food composition for anti-obesity containing a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient.

The compound or a food-acceptable salt thereof may inhibit the differentiation of pre-adipocytes into adipocytes, thereby suppressing the production of lipid droplets or promoting their decomposition.

The compound or a food chemically acceptable salt thereof may be contained in an amount of 0.01 to 1 part by weight based on 100 parts by weight of the total health food composition.

The health food composition may be in the form of a powder, granule, tablet, capsule, jelly, syrup or beverage.

In addition, the present invention provides a pharmaceutical composition for anti-obesity containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

<Formula 1>

The composition according to the present invention suppresses the differentiation of pre-adipocytes into adipocytes to suppress the production of lipid droplets or promote their decomposition, thereby having excellent anti-obesity activity. Obesity or obesity-related diseases can be safely and effectively prevented, ameliorated or treated.

1 shows a chromatogram analyzed by high-performance liquid chromatography according to an embodiment of the present invention.
Figure 2 shows a standard curve of caftaric acid as a function of concentration.
3 is a graph analyzing the cytotoxicity of preadipocytes (3T3-L1) according to an experimental example of the present invention.
Figure 4 shows the results of Oil Red O staining according to an experimental example of the present invention.
5 is a graph obtained by measuring absorbance by eluting the Oil Red O reagent of FIG. 4 .

Hereinafter, the present invention will be described in detail.

The terms used in the present invention have been selected from general terms that are currently widely used as much as possible while considering the functions in the present invention, but these may vary depending on the intention of a person skilled in the art or precedent, the emergence of new technologies, and the like. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, not simply the name of the term.

When it is said that a certain part "includes" a certain component throughout the specification, it means that it may further include other components without excluding other components unless otherwise stated.

The present invention provides an anti-obesity composition containing a compound represented by the following formula (1) or a pharmaceutically or food-acceptable salt thereof as an active ingredient.

<Formula 1>

The compound is a non-flavonoid phenolic compound, (2R,3R)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-3-hydroxy It can be named as hydroxybutanedioic acid {(2R,3R)-2-{[(2E)-3-(3,4-Dihydroxyphenyl)prop-2-enoyl]oxy}-3-hydroxybutanedioic acid}, or It can be named as caftaric acid.

The compound may be used in the form of a pharmaceutically or food-acceptable salt within the scope of having the same efficacy.

In the present specification, "pharmaceutically or food-gradely acceptable" means that the composition is not toxic to cells or humans exposed to the composition.

The salt may be used in the form of any one of a pharmaceutically or food-acceptable basic salt or an acidic salt. The basic salt can be used in the form of any one of an organic basic salt and an inorganic basic salt, and includes sodium salt, potassium salt, calcium salt, lithium salt, magnesium salt, cesium salt, aminium salt, ammonium salt, triethylaminium salt, and pyrol. It may be selected from the group consisting of dinium salts.

As the acid salt, an acid addition salt formed by a free acid is useful. Inorganic acids and organic acids can be used as free acids, and hydrochloric acid, hydrobromic acid, sulfuric acid, sulfurous acid, phosphoric acid, double phosphoric acid, and nitric acid can be used as inorganic acids, and citric acid, acetic acid, maleic acid, malic acid, and fumaric acid can be used as organic acids. , glucoic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid, glutaric acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, Glutamic acid, citric acid, aspartic acid, stearic acid, etc. may be used, but are not limited thereto, and salts formed using various inorganic acids and organic acids commonly used in the art may all be included.

In addition, the compound may include all salts, hydrates, solvates, derivatives, and the like that can be prepared by conventional methods, as well as pharmaceutically or food-acceptable salts. The addition salt can be prepared by a conventional method, and is dissolved in a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile, and an excess organic base is added or an aqueous solution of an inorganic base is added, followed by precipitation or crystallization. can be manufactured by Alternatively, the solvent or excess base may be evaporated from the mixture and then dried to obtain an addition salt, or the precipitated salt may be suction filtered.

The compound or salt thereof may be contained in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the total anti-obesity composition, but is not limited thereto.

The compound or salt thereof may have anti-obesity activity.

In the present specification, "anti-obesity" is meant to cover obesity treatment, prevention, improvement or suppression, and the like.

More specifically, the compound or its salt suppresses the differentiation of preadipocytes into adipocytes to inhibit the production of lipid droplets or promote their decomposition. It can be used as a pharmaceutical composition or health food composition for the prevention, improvement or treatment of obesity or obesity-related diseases using the composition for use.

In the present specification, “obesity” refers to a disease in which an abnormally large amount of fat is accumulated in the body.

Obesity can be prevented, improved, or treated using the anti-obesity composition, and obesity-related diseases such as metabolic complications caused by obesity can be prevented, improved, or treated.

The metabolic complications may include diseases caused by elevated blood levels of triglycerides, cholesterol, and low-density lipids.

More specifically, the metabolic complications include metabolic syndrome (visceral fat syndrome, metabolic syndrome, etc.), hypertriglyceridemia, hypoHDLemia, angina pectoris, myocardial infarction, sexual dysfunction, sleep apnea, premenstrual syndrome, and stress urinary incontinence. Including urinary incontinence, hyperactivity disorder, chronic fatigue syndrome, osteoarthritis, cancer associated with weight gain, orthostatic hypotension, pulmonary hypertension, menstrual disorders, diabetes mellitus, hypertension, impaired glucose tolerance, coronary thrombosis, apoplexy, depression, anxiety, psychosis, Reproductive disorders such as tardive dyskinesia, drug addiction, substance abuse, cognitive impairment, Alzheimer's disease, cerebral ischemia, obsessive-compulsive behavior, panic attacks, social phobia, bulimia, atherosclerosis, gallbladder diseases such as cholelithiasis, anorexia, polycystic ovary disease , infection, varicose veins, skin diseases such as epidermal hyperplasia and eczema, insulin resistance, chronic arterial occlusion, orthopedic injury, thromboembolism, heart disease, urinary disease, lipid syndrome, hyperglycemia, or stress, but is limited thereto it is not going to be

Preferably, the present invention provides a health food composition for anti-obesity containing a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient.

<Formula 1>

Corresponding features may be substituted in the foregoing.

In the health food composition according to the present invention, the health food may be prepared in the form of powder, granule, tablet, capsule, jelly, syrup or beverage for the purpose of preventing or improving obesity-related diseases. There is no limit to the form that the health food can take, and it can be formulated in the same way as a general pharmaceutical composition and used as a functional food or added to various foods.

An effective dose of the compound or salt thereof contained in the health food composition may be appropriately adjusted according to the purpose of use, such as prevention or improvement of obesity or obesity-related diseases.

The compound or a food chemically acceptable salt thereof may be contained in an amount of 0.01 to 1 part by weight, more preferably 0.01 to 0.5 part by weight, based on 100 parts by weight of the total health food composition, but is not limited thereto.

According to one preparation example of the present invention, when the health food composition is in the form of a beverage, it may be contained in an amount of 0.01 to 1 part by weight, more preferably 0.01 to 0.03 part by weight, based on 100 parts by weight of the total health food composition. It is not limited.

When the health food composition is in powder or tablet form, it may be contained in an amount of 0.01 to 1 part by weight, more preferably 0.1 to 0.5 part by weight, based on 100 parts by weight of the total health food composition, but is not limited thereto.

When the health food composition is a jelly type, it may be contained in an amount of 0.01 to 1 part by weight, more preferably 0.1 to 0.3 part by weight, based on 100 parts by weight of the total health food composition, but is not limited thereto.

The health food may include all foods in a conventional sense. For example, beverages and various drinks, fruits and their processed foods (canned fruit, jam, etc.), fish, meat and their processed foods (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), etc., and may include all functional foods in a conventional sense. It may also include food used as feed for animals.

The health food composition may be prepared by further including food chemically acceptable food additives (food additives) commonly used in the art and other suitable auxiliary ingredients. Unless otherwise specified, suitability as a food additive can be determined according to the standards and standards for the item in accordance with the General Rules of the Code of Food Additives approved by the Ministry of Food and Drug Safety and general test methods. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations; and the like.

The other auxiliary ingredients include, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents, etc. may additionally contain. In particular, as the natural carbohydrate, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol may be used. As the sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame may be used.

The health food composition uses food as a raw material and has the advantage of not having side effects that can occur when taking general medicines for a long time, and has excellent portability, so it can be taken as an adjuvant for preventing or improving obesity or obesity-related diseases.

Preferably, the present invention provides a pharmaceutical composition for anti-obesity containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

<Formula 1>

Corresponding features may be substituted in the foregoing.

The pharmaceutical composition according to the present invention can be prepared according to conventional methods in the pharmaceutical field. The pharmaceutical composition may be formulated with an appropriate pharmaceutically acceptable carrier according to the formulation and, if necessary, may further contain excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, and the like. there is. The appropriate carrier and the like do not inhibit the activity and characteristics of the compound according to the present invention or a pharmaceutically acceptable salt thereof, and may be selected differently depending on the dosage form and dosage form.

The pharmaceutical composition may be applied in any dosage form, and more specifically, it may be formulated and used in parenteral dosage forms such as oral dosage forms, external preparations, suppositories and sterile injection solutions according to conventional methods.

Among the oral dosage forms, the solid dosage form is in the form of tablets, pills, powders, granules, capsules, etc., and includes at least one excipient such as starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc. may be prepared by mixing, and lubricants such as magnesium stearate and talc may be included in addition to simple excipients. In addition, in the case of a capsule formulation, a liquid carrier such as fatty oil may be further included in addition to the above-mentioned materials.

Among the oral formulations, liquid formulations include suspensions, solutions for internal use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.

The parenteral formulation may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized formulation, and a suppository. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogeratin, and the like may be used. It is not limited thereto, and all suitable agents known in the art may be used.

In addition, calcium or vitamins may be further added to the pharmaceutical composition to enhance therapeutic efficacy.

The pharmaceutical composition according to the present invention can be administered in a pharmaceutically effective amount.

In the present specification, "pharmaceutically effective amount" means an amount that is sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects.

The effective dose level of the pharmaceutical composition is determined by the purpose of use, the patient's age, sex, weight and health condition, disease type, severity, drug activity, drug sensitivity, administration method, administration time, administration route and excretion rate, treatment Duration, combination, or factors including drugs used concurrently and other factors well known in the medical arts may be determined differently. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg, may be administered once or several times a day. The dosage is not intended to limit the scope of the present invention in any way.

The pharmaceutical composition may be administered to any animal that may develop obesity-related diseases such as obesity or metabolic complications due to obesity, and the animal may include, for example, humans and primates as well as livestock such as cattle, pigs, horses, and dogs. etc. may be included.

The pharmaceutical composition may be administered by an appropriate administration route according to the formulation form, and may be administered through various oral or parenteral routes as long as it can reach the target tissue. The method of administration is not particularly limited, and may be administered by conventional methods such as oral, rectal or intravenous, intramuscular, dermal application, intraventricular inhalation, intrauterine epidural or intracerebroventricular injection.

The pharmaceutical composition according to the present invention may be used alone for the prevention or treatment of obesity or obesity-related diseases, and may be used in combination with surgery or other drug treatment.

In addition, the present invention provides a reagent composition for inhibiting adipocyte differentiation comprising a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient.

<Formula 1>

Corresponding features may be substituted in the foregoing.

Hereinafter, examples will be described in detail to aid understanding of the present invention. However, the following examples are merely illustrative of the contents of the present invention, but the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.

<Example 1> Analysis of caftaric acid

1. Target substance

A caftaric acid standard was purchased from ChemFaces and used.

Table 1 below is information on purchased captaric acid.

CAS water LOT No. formulation caftaric acid 67879-58-7 98.1% CFS202002 powder

2. Material Analysis (HPLC)

The target substance was accurately weighed, and methanol (HPLC grade) was added to completely dissolve the mixture to form a standard stock solution. The standard stock solution was appropriately diluted with methanol to obtain a standard solution.

Table 2 below shows high-performance liquid chromatography (HPLC) analysis conditions.

As a result, as shown in FIGS. 1 and 2, it can be confirmed that the target material is captaric acid.

<Experimental Example 1> Confirmation of anti-obesity activity of caftaric acid

1. Experiment method

1) Experimental model

The 3T3-L1 cell line, which is a mouse progenitor cell line distributed from ATCC (American Type Culture Collection), was used.

2) Culture of preadipocytes

Cultured in DMEM (high-glucose Dulbeco's modified Eagle's medium) medium containing 1% penicillin-streptomycin and 10% newborn calf serum (NBCS) at 37°C and 5% CO ₂ conditions. did The culture medium was exchanged every 2 days.

3) Confirmation of cytotoxicity (survival rate) (WST assay)

Cell viability test (Water soluble tetrazolium salt; WST assay) was performed using EZ-CYTOX (Daeillab service co., Ltd, Seoul, Korea).

3T3-L1 cells were dispensed in a 96-well plate at 1×10 ⁴ cells/well and cultured for 24 hours, and samples were then treated in each well for each concentration. After 24 hours, 10 μL/100 μL of EZ-Cytox was added to each well and reacted in an incubator for 2 hours. Before measuring the absorbance, it was gently shaken for about 1 minute, and the absorbance was measured at 450 nm with an ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA).

4) Induction of differentiation into adipocytes

After equally dispensing 2×10 ⁵ cells/well in a 6-well plate, they were cultured for 48 hours in a 100% confluent state. Culture medium was exchanged every 2 days until differentiation induction.

The composition of the differentiation induction culture medium is shown in Table 3 below.

Culture medium composition first 3 days DMEM (high-glucose Dulbeco's modified Eagle's medium)
10% fetal bovine serum (FBS), 1% penicillin-streptomycin
3-isobutyl-1-methylxanthine (IBMX, 0.5 mM)
Insulin (human, 10μg/ml), dexamethasone (1μM) mid term 3 days DMEM (high-glucose Dulbeco's modified Eagle's medium)
10% fetal bovine serum, 1% penicillin-streptomycin, insulin (human, 10μg/ml) 3 days review DMEM (high-glucose Dulbeco's modified Eagle's medium)
10% fetal bovine serum, 1% penicillin-streptomycin

In addition, as shown in Table 4 below, from the day of induction of differentiation, culture medium and samples were exchanged every day.

Cultures and Samples Normal NBCS Control differentiation exp 1 Differentiation + caftaric acid 1μg/mL exp 2 Differentiation + caftaric acid 2μg/mL exp 3 Differentiation + caftaric acid 5μg/mL exp 4 Differentiation + caftaric acid 10μg/mL

5) Oil red O staining

In the process of differentiating from preadipocytes to adipocytes, Oil red O staining was performed to measure the effect on adipocyte differentiation.

According to the cell culture and differentiation induction protocol, samples were exchanged with DMEM culture medium containing 10% FBS including an adipogenic cocktail every day, and Oil red O staining was performed at the late stage of differentiation (9th day).

The culture medium was suctioned and washed twice with the PBS solution, and then the PBS solution was completely suctioned again. After adding 10% formalin and fixing at room temperature for 5 minutes, suctioning 10% formalin and then adding new 10% formalin and fixing at room temperature for more than 2 hours, suctioning formalin and adding 60% isopropanol Immediately after suction, the flask was dried completely.

Oil red O solution was added thereto to stain fat globules for 60 minutes. After staining, the intracellular accumulation of fat globules was observed with a microscope and a camera by washing with distilled water 4 times. Oil red O dye was eluted by adding 100% isopropanol in a well-dried state to quantify the amount of fat globules accumulated. Then, the optical density was measured at a wavelength of 520 nm using an ELISA reader (Molecular Devices, USA).

2. Experimental results

1) Confirmation of cytotoxicity and viability

Table 5 below measures the cell viability according to the concentration of caftaric acid.

Referring to Table 5 and FIG. 3, captaric acid did not show toxicity up to 40.0 μg/mL, and even when dimethyl sulfoxide (DMSO) was treated at a concentration of 1% as a solvent for dissolving the sample, toxicity and specific results did not appear

2) Check the results of Oil Red O staining

Referring to FIG. 4, when caftaric acid is administered, it can be directly confirmed that the number of lipid droplets is smaller than that of the control, and it can be confirmed that fat droplets show a distinct difference depending on the administration concentration during staining. can

Table 6 below shows the results of measuring absorbance by eluting the Oil Red O reagent.

Referring to Table 6 and FIG. 5, it can be confirmed that the absorbance measurement result also significantly differs depending on the caftar acid treatment.

That is, through this, it can be confirmed that captaric acid has anti-obesity activity by inhibiting fat formation or promoting decomposition.

Hereinafter, formulation examples of the composition containing caftaric acid according to the present invention will be described, but the present invention is not intended to be limited, but only specifically described.

<Production Example 1> Beverage production

Table 7 below shows formulations for preparing beverages containing caftaric acid according to the present invention and their mixing ratios.

division material name combination(%) One caftaric acid 0.025 2 erythritol 10.000 3 Enzymatically Treated Stevia 0.050 4 grape concentrate 0.120 5 acesulfame potassium 0.002 6 citric acid 0.300 7 sodium citrate 0.050 8 vitamin C 0.050 9 Natural fragrance (shine muscat scent) 0.150 10 carbon dioxide 0.600 11 Purified water 88.653 total 100.000

<Preparation Example 2> Manufacture of health food

2-1. powder and tablet

Table 8 below shows preparations for preparing health food in powder or tablet form containing captaric acid according to the present invention and their mixing ratios.

division material name combination(%) One caftaric acid 0.330 2 erythritol 85.130 3 Enzymatically Treated Stevia 0.500 4 Lemon Juice Powder 0.500 5 (anhydrous) citric acid 3.000 6 trisodium citrate 0.400 7 indigestible maltodextrin 7.000 8 vitamin C 0.400 9 Natural flavoring (lemon flavor) 1.600 10 Vitamin B1 hydrochloride 0.070 11 Vitamin B6 hydrochloride 0.070 12 silicon dioxide 1.000 total 100.000

2-2. jelly

Table 9 below shows formulations and their mixing ratios for preparing a jelly-type health food containing caftaric acid according to the present invention.

division material name combination(%) One caftaric acid 0.250 2 erythritol 40.000 3 Enzymatically Treated Stevia 0.100 4 apple concentrate 0.500 5 citric acid 0.450 6 sodium citrate 0.050 7 vitamin C 0.050 8 Natural flavoring (apple flavor) 0.200 9 Vitamin B1 hydrochloride 0.070 10 Vitamin B6 hydrochloride 0.070 11 Food Gel F 2.000 12 Purified water 56.260 total 100.000

Having described specific parts of the present invention in detail above, it is clear that these specific techniques are merely preferred embodiments for those skilled in the art, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof. The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included in the scope of the present invention.

Claims (5)

A health food composition for anti-obesity containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
<Formula 1>

According to claim 1,
The compound or a food acceptable salt thereof,
A health food composition for anti-obesity, characterized in that by suppressing the differentiation of pre-adipocytes into adipocytes to inhibit the production of fat droplets or to promote their decomposition.
According to claim 1,
The compound or a food acceptable salt thereof,
A health food composition for anti-obesity, characterized in that it is contained in an amount of 0.01 to 1 part by weight, based on 100 parts by weight of the total health food composition.
According to claim 1,
The health food composition,
A health food composition for anti-obesity, characterized in that in the form of powder, granule, tablet, capsule, jelly, syrup or beverage.
An anti-obesity pharmaceutical composition comprising a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient.
<Formula 1>

Images